Okyo Pharma Surges 12% as Investor Optimism Drives Biotech Stock Gains
Okyo Pharma surges 12%—a mid‑cap biotech hit driven by eye‑disease innovation and rising investor optimism.
- OKYO PHARMA LTD
- United Kingdom
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read